Investor Presentaiton

Large and Diverse Client Base Provides Stability and Sustained Growth ■ Most of top 25 clients are large biopharmaceutical companies ◉ Capital market dependent (CMD) public biotechs with <2 years cash represent only ~5% of revenue ■ Strong client overlap between business segments with opportunity to further capture incremental client wallet share Revenue by Client Segment* CRL New Biotech Clients Added** >2,000 Biopharma clients in 2022 Largest client <3% of total FY 2022 revenue -20% -10% -30% Charles River Laboratories (CRL) 673 591 564 533 ■ Biotech -40% ■ Globals ■ Other ■ Academic/ Government FY FY FY FY 2019 2020 2021 2022 * CRL revenue by client segment based on FY 2022 revenue. ** New biotech clients updated for full-year data for each period. Top 25 clients -30% of total FY 2022 revenue 14

View entire presentation